Close
FINDING CURES TOGETHER<sup>SM</sup>

Regulatory Science and Policy Subcommittee

The AACR established the Regulatory Science and Policy Subcommittee in March of 2011 to support the FDA’s endeavor to modernize the regulatory process and accommodate the fast pace of innovation in science and technology. The subcommittee leads the AACR’s efforts to facilitate scientific exchange among stakeholders from academia, industry, advocacy, and government to unleash the true potential of regulatory science to serve patients. In order for the latest research to inform regulators, regulatory guidelines and regulatory policy, regulators must keep abreast with developments in cancer research. Scientists also benefit from an understanding of the regulatory process, which can facilitate their own research programs and speed the translation of discoveries into new and improved interventions.

The subcommittee is dedicated to bringing together and providing an open forum for stakeholder engagement. It is also actively engaged in the development and implementation of programmatic and policy initiatives to improve the development, evaluation and regulation of cancer drugs, biologics and diagnostics.


Signature initiatives of the subcommittee include:
   

2018-2019 Subcommittee Members     

Click here for a printer-friendly version of the subcommittee roster

Kenneth C. Anderson, MD
Subcommittee Chairperson
Program Director and Chief, Division of Hematologic Neoplasia, Kraft Family Professor of Medicine
Harvard Medical School, Dana-Farber Cancer Institute
Boston, MA


James L. Abbruzzese, MD, FACP
Chief, Division of Medical Oncology, Department of Medicine, Associate Director for Clinical Research
Duke Cancer Institute
Durham, NC
 
José Baselga, MD, PhD
Physician-in-Chief
Mem. Sloan Kettering Cancer Ctr.
New York, NY

William S. Dalton, PhD, MD
Founder and Chief Executive Officer
M2Gen
Tampa, FL
 
Raymond N. DuBois, MD, PhD
Dean, College of Medicine
Medical Univ. of South Carolina
Charleston, SC
 
Howard J. Fingert, MD, FACP
Senior Medical Director for Clinical Intelligence
Takeda Pharmaceuticals, Inc.
Cambridge, MA
 
Susan M. Galbraith, MD, PhD
Head of Oncology Innovative Medicines
AstraZeneca
Cambridge, England

Judy E. Garber, MD, MPH
Director, Center for Cancer Genetics and Prevention
Dana-Farber Cancer Institute
Boston, MA
 
Levi A. Garraway, MD, PhD
Sr. VP Global Development and Medical Affairs, Lilly Oncology
Eli Lilly and Company
Indianapolis, IN
 
Richard B. Gaynor, MD
President, Research and Development
Neon Therapeutics
Cambridge, MA
 
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine, Associate Director for Translational Research
Yale Cancer Center
New Haven, CT
 
Sandra J. Horning, MD
Global Head of Product Development, Chief Medical Officer
F. Hoffman-LaRoche, Ltd.
South San Francisco, CA
 
Pasi A. Jänne, MD, PhD
Director, Lowe Center for Thoracic Oncology
Scientific Director, Belfer Institute for Applied Career Science
Dana-Farber Cancer Institute
Boston, MA

Chitkala Kalidas, PhD
Vice President, Head Oncology Regulatory Affairs
Bayer

New York, NY

Peter F. Lebowitz, MD, PhD
SVP, Global Therapeutic Area Head, Oncology
Janssen Research & Development, LLC
Wayne, PA

John E. Leonard, PhD
Senior Vice President, Development
Vaccinex Inc.
Rochester, NY
 
Thomas J. Lynch, Jr, MD
Executive Vice President & CSO
Bristol-Myers Squibb Co.
New York, NY
 
Mace L. Rothenberg, MD
Senior Vice President, Clinical Development and Medical Affairs
Pfizer Oncology
La Jolla, CA
 
David M. Reese, MD
Vice President, Medical Sciences
Amgen Inc.
Los Angeles, CA
 
Eric H. Rubin, MD
Vice President & Therapeutic Area Head, Oncology Early Dev.
Merck
 
Charles L. Sawyers, MD
Chair, Human Oncology & Pathogenesis Program
Memorial Sloan Kettering Cancer Center
New York, NY
 
Mehdi Shahidi, MD
Corporate Vice President, Global Head of Medicine, Oncology
Boehringer Ingelheim
Sutton, England
 
Ellen V. Sigal, PhD
Chairperson and Founder
Friends of Cancer Research
Washington, DC
 
Suzanne L. Topalian, MD
Professor, Surgery and Oncology, Johns Hopkins University School of Medicine
Director, Melanoma Program, Sidney Kimmel Cancer Center
Johns Hopkins University
Sidney Kimmel Cancer Center
Baltimore, MD
 
Laura J. van 't Veer, PhD
Professor, Department of Laboratory Medicine
UCSF Helen Diller Family Comprehensive
San Francisco, CA
 
Victor E. Velculescu, MD, PhD
Co-Director of Cancer Biology and Professor of Oncology
Johns Hopkins Kimmel Comprehensive
Baltimore, MD

AACR Staff Contact

Sarah Martin, MS, PhD, Senior Regulatory Science and Policy Analyst

AACR Office of Science Policy and Government Affairs
Email or call 267-765-1029

Top of page